CCN5 activation by free or encapsulated EGCG is required to render triple‐negative breast cancer cell viability and tumor progression

Pharmacology Research & Perspectives

Amlan Das¹  Indranil Chatterjee¹  Archana De¹  Inamul Haque¹  Snigdha Banerjee²  Arnab Ghosh²  Sushanta K. Banerjee³  Priyanka Ray⁴  Mohiuddin Quadir⁵  Debasmita Dutta⁵  Sumedha Gunewardena⁶  Scott Weir⁷ 

[1] Cancer Research Unit, VA Medical Center, Kansas City, MO, USA;Cancer Research Unit, VA Medical Center, Kansas City, MO, USA;Department of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, KS, USA;Cancer Research Unit, VA Medical Center, Kansas City, MO, USA;Department of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, KS, USA;Lead contact, SKB, Cancer Research Unit, Kansas City, MO, USA;Department of Chemical Biochemical Environmental Engineering (CBEE, University of Maryland, Baltimore, MD, USA;Department of Coatings and Polymeric Materials, North Dakota State University, Fargo, ND, USA;Department of Molecular and Integrative Physiology, University of Kansas Medical Center, Kansas City, KS, USA;Department of Pharmacology, Toxicology and Therapeutics, University of Kansas Medical Center, Kansas City, KS, USA;

关键词: bioavailability;    breast cancer;    CCN5;    drug delivery;    EGCG;    FA‐PEG‐NPs;    folic acid;    nanoparticles;    PCNA;    TNBC;   

DOI  :  10.1002/prp2.753

来源: Wiley

【 授权许可】

CC BY